Outsourcing in Clinical Trials Southeast 2014March 4-5, 2014, Cary, NC
North Carolina: the epicenter of the biotech and CRO industries...
Outsourcing in Clinical Trials Southeast has become the leading roadshow for the pharmaceutical, biotech and medical device industries in North Carolina and the Southeast United States.
Now in its 3rd exciting year, OCT Southeast will take an in-depth look at the challenges and opportunities facing small to medium drug developers and their clinical partners.
Learn about the essential tools for effective vendor selection and partnership optimization that every clinical professional should have in their arsenal. Hear how to achieve excellence in data management and clinical study informatics. Plus: expert advice on funding and investment, as well as the latest in patient recruitment and trial monitoring.
Benefit from an unrivalled line up of speakers, including 11 small/medium and biotech, 8 c-level presenters, leading academics, investors and clinical experts
The 3rd Annual Outsourcing in Clinical Trials Southeast is an essential platform for biotech, pharma and medical device professionals from North Carolina and surrounding states, to discuss specific challenges, identify key opportunities and network with peers and partners in the Southeast region.
OCT Southeast is designed in collaboration with local industry experts, who play a key role in ensuring the agenda content is exactly what clinical outsourcing professionals like you need in order to maximise the value of your conference experiences.
The beauty of this unique event is its truly local reach, and roster of specifically tailored topics, expert speakers and fruitful networking sessions. OCT Southeast 2014 will help you achieve optimal results from your clinical outsourcing programs.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Outsourcing in Clinical Trials Southeast boasts a fantastic exhibition of outsourcing service providers and industry specialists. Our exhibition area is already filling up due to the fantastic event which took place in May 2013.
We are always happy to see photos taken at our events! If you have any you would like to submit, please email email@example.com The Arena Team
Contract Research Organization, Clinovo tells us about their experience and takeaways from Outsourcing in Clinical Trials Southern California.
With focused sessions, interactive panel discussions and peer-to-peer networking, this event will offer delegates a forum in which to learn more about the challenges, innovations and opportunities impacting clinical outsourcing in the RPT area, as well as how local CROs and service providers can deliver customised solutions.
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout The Research Triangle Park.
US-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor 'veliparib (ABT-888)' in patients with previously untreated locally …
Sweden-based Aprea, a Karolinska Development portfolio company, has started dosing patients in the Phase I/II clinical trial of APR-246 in combination with chemotherapy to treat ovarian cancer.
US-based biopharmaceutical firm Lexicon Pharmaceuticals has reported positive, top-line results from a Phase II clinical trial of LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), for the treatm…
UK-based biotechnology firm Critical Pharmaceuticals has announced the start of the first Phase I clinical trial of a nano-enabled intranasal teriparatide product in healthy post-menopausal women for the treatment of osteoporosis.
Merck has reported interim results from the ongoing C-WORTHy study, a multi-arm Phase II clinical trial assessing the efficacy and safety of an all-oral, once-daily regimen combining MK-5172 and MK-8742 in patients with chronic HCV Genotype 1 infecti…